Needham reiterates CRISPR Therapeutics AG (CRSP) rating to a Buy
In a filing, CRISPR Therapeutics AG revealed its General Counsel and Secretary KASINGER JAMES R. unloaded Company’s shares for reported
In a filing, CRISPR Therapeutics AG revealed its General Counsel and Secretary KASINGER JAMES R. unloaded Company’s shares for reported
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
CRISPR Therapeutics AG’s recently made public that its General Counsel and Secretary KASINGER JAMES R. unloaded Company’s shares for reported
CRISPR Therapeutics AG’s recent filing unveils that its General Counsel and Secretary KASINGER JAMES R. unloaded Company’s shares for reported
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CRISPR Therapeutics
CRISPR Therapeutics AG’s recently made public that its Chief Operating Officer Bruno Julianne unloaded Company’s shares for reported $0.19 million
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CRISPR Therapeutics
CRISPR Therapeutics AG’s recent filing unveils that its Chief Operating Officer Bruno Julianne unloaded Company’s shares for reported $0.19 million
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.